Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer

Autor: Van Der Noll, Ruud, Marchetti, Serena, Steeghs, Neeltje, Beijnen, Jos H., Mergui-Roelvink, Marja W J, Harms, Emmy, Rehorst, Harriet, Sonke, Gabe S., Schellens, Jan H M, Pharmacoepidemiology and Clinical Pharmacology, Sub Clinical Pharmacology

Publikováno v: British Journal of Cancer, 113(3), 396. Nature Publishing Group
British Journal of Cancer

Background: Olaparib (AZD2281), a PARP-1/2 inhibitor, has been extensively investigated in clinical trials. However, limited clinical data are available about its long-term safety and anti-tumour activity. Methods: Patients had first participated in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0a4c424915e6bc15ab20fe09b631174
https://dspace.library.uu.nl/handle/1874/327611

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.

Autor: van der Noll R; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands., Marchetti S; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands., Steeghs N; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands., Beijnen JH; 1] Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands [2] Utrecht Institute of Pharmaceutical Sciences (UIPS), Utrecht University, Universiteitsweg 99, Utrecht 3584 CG, The Netherlands., Mergui-Roelvink MW; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands., Harms E; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands., Rehorst H; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands., Sonke GS; Department of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands., Schellens JH; 1] Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands [2] Utrecht Institute of Pharmaceutical Sciences (UIPS), Utrecht University, Universiteitsweg 99, Utrecht 3584 CG, The Netherlands.

Publikováno v: British journal of cancer [Br J Cancer] 2015 Jul 28; Vol. 113 (3), pp. 396-402. Date of Electronic Publication: 2015 Jul 16.